Business Wire

Dixa and weWow Launch Strategic CX Partnership for Scale-ups

1.11.2021 17:58:00 EET | Business Wire | Press release

Share

Dixa, the European leader in CX technology, and weWow, the boutique customer service company that focuses only on fast-growing scale-ups, are joining forces to serve fast-growing companies in their growth trajectory. The Copenhagen and Valencia-based companies are presenting their partnership at the Web Summit this November in Lisbon.

“We believe that fast-growing companies nowadays require a combination of great technology and very talented people to serve their customers in the best way,” says Mads Fossilus, CEO of Dixa. “Both weWow and Dixa have a clear focus on fast-growing companies since we are both coming from this space ourselves. With our partnership, we combine great technology with the best people in CS, and we want to offer the knowledge we have gathered over the years to help those companies grow even faster than they currently do.”

“Fast-growing companies have different needs than traditional companies can offer,” says Marije Sluis, Growth Lead of weWow. “Growing your operation is painful, but completely outsourcing your customer service is risky and impersonal. That’s why we offer the option of co-scaling; Building the best team and technology together with those companies, as a scalable arm to their own teams. With weWow and Dixa, our partners are ready to scale without hassle.”

Discount for Scale Ups for the First Year

The partnership provides a compelling entry period, in which both companies offer their services at reduced rates, which will enable scale-ups to receive the full value of the partnership, without the full financial investment.

Shane McNulty, VP of Partners at Dixa and Hans Scheffer, Founding Partner at weWow, added: “We know that we deliver better results in terms of Employee Happiness, Customer Happiness and overall efficiency, and we firmly believe that innovative CX technology, with great human talent, results in value adding services - that’s what makes the difference. That’s why we offer our partners the opportunity to work with us at reduced rates during this period, to prove the value we can deliver to your customers.”

CX Lab with the newest technology

To demonstrate the power of technology and great people, Dixa and weWow are creating a brand new CXLab in Valencia. “Scale-ups can see, feel and experience here in a live environment how we do Customer Service fueled by great technology in a different way,” says Sluis. “So no demos, but a true experience on how technology works. We do this not only with Dixa but also with many integrated technology partners and tools that today’s Customer Service Agents need to perform successfully.” The CXLab will open on the 1st of December.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Connor O’Keefe
Fire on the Hill
dixa@fireoth.com
+44(0)7710685742

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 09:00:00 EEST | Press release

Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521069859/en/ Boomi Named One of The Sunday Times Best Places to Work 2026 Boomi's results speak to a workplace culture that goes well beyond industry norms. The company achieved an average employee happiness score of 86%, rated Excellent, with consistent scores across all six dimensions of WorkL's framework. Most strikingly, Boomi's flight risk, the proportion of employees who may be considering leaving, stood at just 3%, against a technology se

LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 08:09:00 EEST | Press release

LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through centers in Romania and Portugal. This would create a more diversified portfolio for LTM – expanding its scale in Europe and Australia, enhancing its position in regulated and high-growth verticals through marquee customer relationships. The deal would augment LTM’s global AI-centric capabilities with local domain and near-shore expertise crucial for delivering digital an

Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 08:00:00 EEST | Press release

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye